MAPEA

MAPEA
Clinical data
Other names3-Methoxy-4-allyloxyphenethylamine; 4-Allyloxy-3-methoxyphenethylamine; ALLOMPEA; 3-Desmethoxyallylescaline
Routes of
administration
Oral
Drug classPsychoactive drug; "Mood elevator"
ATC code
  • None
Identifiers
  • 2-(3-methoxy-4-prop-2-enoxyphenyl)ethanamine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H17NO2
Molar mass207.273 g·mol−1
3D model (JSmol)
  • COC1=C(C=CC(=C1)CCN)OCC=C
  • InChI=1S/C12H17NO2/c1-3-8-15-11-5-4-10(6-7-13)9-12(11)14-2/h3-5,9H,1,6-8,13H2,2H3
  • Key:DVMQMRGYKZBKKX-UHFFFAOYSA-N

MAPEA, also known as 3-methoxy-4-allyloxyphenethylamine or as 3-desmethoxyallylescaline, is a psychoactive drug of the phenethylamine family related to the psychedelic drug and scaline allylescaline. It is the 3-desmethoxy analogue of allylescaline. The drug is said to be a "mood elevator" at doses of 100 to 300 mg orally, in contrast to related drugs like allylescaline which are psychedelic hallucinogens. The chemical synthesis of MAPEA has been described. MAPEA was first described in the scientific literature by Otakar Leminger in 1972. Subsequent, it was further described by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.

See also